David Soergel - 04 Mar 2026 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Reporting relationship: Chief Medical Officer
Issuer ticker: MDGL
Reported as of: 04 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Mar 2026, 17:55:58 UTC
Prior SEC filing: 16 May 2025
Next SEC filing: 18 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Mardi Dier, as Attorney-in-Fact

Key filing fact

David Soergel filed Form 4 for MADRIGAL PHARMACEUTICALS, INC. (MDGL) on 06 Mar 2026.

Key facts

This page summarizes David Soergel's Form 4 filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Mar 2026, 17:55.

Change

Previous filing in this sequence was filed on 16 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001591475 Primary reporting owner

Soergel David

Relationship: Chief Medical Officer
Address: C/O MADRIGAL PHARMACEUTICALS, INC., 200 BARR HARBOR DRIVE, SUITE 200, WEST CONSHOHOCKEN
Signature: /s/ Mardi Dier, as Attorney-in-Fact
Signature date: 06 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MDGL transaction

Common Stock

Award

Transaction value
Shares: +4,374
Change %: +58%
Price: $0.000000^*
Shares after: 11,919
Date: 04 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MDGL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +5,467
Change %
Price: $0.000000^*
Shares after: 5,467
Date: 04 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,467
Exercise price: $434.80
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date.

Footnote F2

The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.